Investors

Message from the CEO

”SynAct is in a fortunate position now as the company has two development tracks, across both autoimmune and infection-driven inflammation, for resomelagon.”

Read the full letter

Latest news and press releases

Press releases

February 6, 2026 - Non-regulatory

SynAct Pharma successfully reached recruitment goal in Ph2b ADVANCE study

Press releases

January 30, 2026 - Non-regulatory

SynAct Pharma initiates Phase 2 study in respiratory insufficiency

Press releases

January 19, 2026 - Regulatory

SynAct Pharma appoints Malin Wikstrand as interim CFO

All press releases

Calendar

All calendar events

Subscribe to press releases
and reports

Get the latest news follow us on Linkedin

Message from the CEO

Latest news and press releases

Calendar

Subscribe to press releases and reports

Subscribe to press releases
and reports